Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults

Author's Avatar
Feb 11, 2022

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of cumulative 5-year results from two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF). The new, long-term data further demonstrate the sustained efficacy and safety profile and lack of treatment failure due to resistance in the final resistance analysis population associated with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022).